The Prostate Cancer Foundation VL

Prostate Cancer Disparities: A Global Lens - Edward Christopher Dee

Details
Edward Christopher Dee discusses racial disparities in prostate cancer treatment and outcomes in the UK and US, highlighting findings from his team's Nature Reviews Urology publication. Drawing from multiple studies, including analysis of the National Cancer Database and VA health systems, he demonstrates how Black and Asian patients face higher rates of treatment refusal and delays compared to wh...

AR EcDNA Discovery in Advanced Prostate Cancer Study - George Zhao

Details
George Zhao joins Andrea Miyahira to discuss research examining three-dimensional genome organization in metastatic prostate cancer. The study integrates multi-omic data including RNA-seq, whole-genome sequencing, and Hi-C sequencing. Their key finding reveals that approximately one-third of samples show disrupted genomic organization around the androgen receptor (AR) gene, which they discover is...

VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery

Details
Neeraj Agarwal leads a discussion with Martin Schoen and Bruce Montgomery about a study examining treatment patterns and outcomes for veterans with metastatic hormone-sensitive prostate cancer. The research reveals that VA patients demonstrate longer survival rates compared to the general U.S. population, particularly among younger patients, with combination therapy now being utilized in approxima...

Exercise Benefits In Prostate Cancer Active Surveillance - Dong-Woo Kang

Details
Dong-Woo Kang joins Andrea Miyahira to discuss his team’s research on high-intensity interval training in prostate cancer patients undergoing active surveillance. The study examines the effects of a 12-week supervised aerobic exercise program on cardiometabolic biomarkers and cancer-related outcomes. The conversation highlights significant findings, including improvements in PSA levels, cancer cel...

Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel

Details
Andrea Miyahira hosts Steven Kregel to discuss a published paper on humanized mouse models for metastatic prostate cancer. Dr. Kregel discusses the challenges of modeling prostate cancer in mice and introduces humanized mouse models that better recapitulate human immune responses. He explains how these models, developed using human hematopoietic stem cells, allow for the study of cancer therapies...

Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan

Details
Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...

Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo

Details
Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...

NSD2's Role in Prostate Cancer: Uncovering AR's Functional Duality - Abhijit Parolia

Details
Andrea Miyahira interviews Abhijit Parolia about his group's study on NSD2's role in prostate cancer. Dr. Parolia explains how NSD2, a histone methyltransferase, reprograms androgen receptor (AR) activity in prostate cancer cells. The research reveals that NSD2 is upregulated in malignant prostate tissue and is crucial for AR binding to chimeric AR-FOXA1 sites, promoting tumor growth. Using CRISPR...

Mentorship and Opportunity: Keys to Success in Medicine - Veda Giri

Details
Veda Giri discusses her roles as director of the Cancer Genetics and Prevention Program and the Early-Onset Cancer Program at Yale Cancer Center, highlighting her path through medical school, where her interest in genetics and patient care deepened. Her career was significantly shaped by mentors and opportunities that arose during her residency and fellowships, emphasizing the importance of mentor...

Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova

Details
Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...